Rubella Diagnostic Testing Industry Forecast to Hit $1.78 Billion by 2029 With a Strong 6.5% CAGR

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Rubella Diagnostic Testing Market?

The rubella diagnostic testing market size has experienced significant growth in recent years. It is forecast to increase from $1.3 billion in 2024 to $1.39 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.7%. The expansion seen in the past can be attributed to an increase in vaccination programs, a growing occurrence of immunization-preventable outbreaks, government efforts to combat the rubella virus, and the wider availability of diagnostic testing in non-traditional environments.

The rubella diagnostic testing market is anticipated to experience substantial expansion in the coming years. It is projected to reach $1.78 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast timeframe is attributable to factors such as increasing healthcare spending, a heightened emphasis on preventive healthcare, enhanced understanding of vaccine-preventable illnesses, expanding public health initiatives, and the broader adoption of telemedicine and remote diagnostic solutions. Key trends expected over the forecast period encompass innovations in diagnostic technologies, the integration of technology within healthcare systems, the creation of point-of-care testing solutions, the evolution of novel diagnostic approaches, and progress in molecular diagnostics.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19177&type=smp

What Are The Main Drivers Boosting The Rubella Diagnostic Testing Industry’s Expansion?

The anticipated increase in viral infection occurrences is projected to stimulate the expansion of the rubella diagnostic testing market in the future. These infections are conditions resulting from viruses, which are minuscule infectious agents capable of multiplying solely within the living cells of a host. The surge in viral infection cases is attributed to heightened global travel, promoting cross-border virus dissemination, and climate change, which modifies vector environments and broadens the distribution of disease-carrying entities. Early identification and management of rubella infections are facilitated by rubella diagnostic testing, thereby averting complications, especially for pregnant women, and assisting in outbreak containment to curtail virus transmission. As an illustration, during December 2023, the National Health Service, a UK government body, reported an average of 234 daily hospital admissions for flu, representing a 53% rise from the prior week. Concurrently, norovirus hospital cases climbed by 15% to an average of 406 per day, indicating a 28% increase compared to the equivalent week last year. Consequently, the increasing prevalence of viral infections is stimulating the growth of the rubella diagnostic testing market.

What Are The Major Segment Types Covered In The Rubella Diagnostic Testing Market?

The rubella diagnostic testingmarket covered in this report is segmented –

1) By Diagnostic Technique: Latex Agglutination; Liver Function Tests; Enzyme Immunoassay (EIA); Radioimmunoassay (Ria); Fluorescent Immunoassay (FIA); Other Diagnostic Techniques

2) By Age Group: Neonates; Teenagers; Adults

3) By End User: Hospitals And Clinics; Cancer Diagnostic Centers; Ambulatory Surgical Centers; Other End Users

Subsegments:

1) By Latex Agglutination: Qualitative Latex Agglutination Tests; Quantitative Latex Agglutination Tests; Rapid Latex Agglutination Kits

2) By Liver Function Tests: Serum Bilirubin Tests; Alanine Aminotransferase (ALT) Tests; Aspartate Aminotransferase (AST) Tests; Alkaline Phosphatase (ALP) Tests; Other Liver Enzyme Tests

3) By Enzyme Immunoassay (EIA): Direct EIA; Indirect EIA; Sandwich EIA; Competitive EIA

4) By Radioimmunoassay (RIA): Standard RIA; Modified RIA; Single-Antibody RIA

5) By Fluorescent Immunoassay (FIA): Direct FIA; Indirect FIA; Sandwich FIA

6) Other Diagnostic Techniques: Polymerase Chain Reaction (PCR); Nucleic Acid Amplification Tests (NAAT); Microplate-Based Assays; Western Blotting

Which Market Trends Are Creating New Opportunities In The Rubella Diagnostic Testing Industry?

Companies involved in the rubella diagnostic testing market are prioritizing the creation of novel solutions, including the rubella virus vaccine, to boost diagnostic precision and strengthen preventive actions. This rubella virus vaccine confers protection against rubella, commonly delivered within the MMR or MMRV combination vaccines to avert the illness and related health issues. As an illustration, in March 2023, the US-based pharmaceutical firm Merck & Co., Inc. secured FDA approval for Merck’s M-M-R II vaccine to be given via intramuscular (IM) injection, a key step in guarding against rubella, alongside measles and mumps. This endorsement permits medical professionals to administer the rubella vaccine intramuscularly, aligning it with standard pediatric immunizations. Vaccinating against rubella is vital for stopping outbreaks and shielding individuals from the virus’s serious complications, especially for expectant mothers.

Which Key Players Are Driving Competition In The Rubella Diagnostic Testing Market?

Major companies operating in the rubella diagnostic testing market are Cardinal Health Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., bioMérieux S.A., Bio-Rad Laboratories Inc., Ortho-Clinical Diagnostics Inc., DiaSorin S.p.A., Meridian Bioscience Inc., Fortress Diagnostics Ltd., Mylab Discovery Solutions Pvt. Ltd., MP Biomedicals LLC, CTK Biotech Inc., ZEUS Scientific Inc., Creative Diagnostics, Arlington Scientific Inc., AccuBioTech Co. Ltd., Intec Products Inc., Vitrosens Biotechnology Ltd., Sprint Diagnostics Pvt. Ltd., InDevR Inc., Atlas Medical GmbH

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/rubella-diagnostic-testing-global-market-report

How Is Rubella Diagnostic Testing Market Demand Varying Across Different Regions?

North America was the largest region in the rubella diagnostic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rubella diagnostic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Rubella Diagnostic Testing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=19177&type=smp

Browse Through More Reports Similar to the Global Rubella Diagnostic Testing Market 2025, By The Business Research Company

Bone And Mineral Diagnostic Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bone-and-mineral-diagnostic-testing-global-market-report

Transplant Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/transplant-diagnostics-global-market-report

Molecular Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795